ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.…
ENDRA Life Sciences (NASDAQ: NDRA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 3.575 USD on 20 November 2026, down 31.6% over 52 weeks. Its 52-week range is 2.960 USD to 6.950 USD: the price is 48.6% below the high and 20.8% above the low.
Its market capitalisation is 5.36M USD.
ENDRA Life Sciences reports return on equity of -310.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.12M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.